Unique Features

  • Exceptional sensitivity and reproducible results – meeting clinicians’ needs for monitoring therapy effectiveness, identifying non-adherent and non-responders to therapy
  • Excellent correlation to established CTX-I assays – allowing seamless transition between methods
  • Combining bone turnover markers with the established IDS-iSYS 25-Hydroxy Vitamin DS and IDS-iSYS Intact PTH tests from a single sample tube – aiding management of osteoporosis and other metabolic bone diseases
  • A reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
  • Reduced tube handling – wide variety of sample types supported
  • A complete clinical assay panel supporting bone disease management

The IDS-iSYS CTX-I (CrossLaps®) Assay is intended for the quantitative determination of degradation products of C-terminal telopeptides of Type I collagen (CTX-I) in human serum or plasma on the IDS-iSYS Multi-Discipline Automated System.

Results are to be used in conjunction with other clinical and laboratory data to assist the clinician. CTX-I can be used as an indicator of bone resorption status as well as an aid in monitoring bone resorption changes during hormone replacement and bisphosphonate therapies.

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone1.

During renewal of the skeleton, Type I collagen is degraded and small peptide fragments are excreted into the bloodstream.Serum levels of these degradation products, such as CTX-I, are highly correlated with the bone turnover rate and allow an assessment of the rate of bone resorption.

As of late 2010, IOF and IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) recommend the serum CTX-I to be used as a bone resorption marker for use in observational and intervention studies, in order to compare the performance of alternatives and to widen international experience of the application of bone markers to clinical medicine2.

Michelsen J et al. Bone. Reference intervals for serum concentrations of three bone turnover markers for men and women. 2013 Dec;57(2):399-404.

Vasikaran SD et al. Markers of bone turnover for the prediction of fracture

Vasikaran SD et al. International Osteoporosis Foundation and International